NY-FGS-GLOBAL
21.11.2023 14:01:39 CET | Business Wire | Press release
FGS Global announced today that it has acquired Longview Communications and Public Affairs, bringing together two of the world’s leading communications and public affairs advisory firms. FGS will now be able to serve clients more extensively throughout North America, with a deeply experienced team across eight offices in the United States and three offices in Canada. FGS’s approximately 1,300 professionals around the world offer an integrated suite of capabilities, with deep local relationships and extensive knowledge across industries and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121931472/en/
Celebrating its 20th anniversary this year, Longview is the Canadian market leader, advising clients on corporate and financial communications, issues and crisis management, special situations, government relations, regulatory affairs and foreign direct investment approvals. Consistently ranked among the top 15 global PR advisors on M&A and shareholder activism, Longview advises a wide range of leading Canadian companies, as well as numerous global companies operating across the country. Its team of over 30 professionals brings extensive experience and relationships at the highest levels of government, media and business, and provides the firm’s clients an integrated service offering across disciplines that is unmatched in Canada.
Winnie Lerner, FGS’s Chief Executive Officer, North America, said, “Longview is the go-to team on all mission critical issues for companies in Canada. The firm has an outstanding track record, deep client relationships, and values aligned with our own. Extending our reach into Canada broadens our geographic footprint and enhances our ability to deliver for our clients. We have known and respected Longview for a long time, have partnered successfully on many prior client assignments and are thrilled to welcome them to FGS.”
Josh Pekarsky, Founder and Managing Partner at Longview, said, “Longview has always been about doing great work for our clients. This transaction furthers that goal and provides an exceptional platform for the future. We have been impressed by the quality and thoughtfulness of what FGS is building and are delighted to become part of this leading global platform as we embark on this next chapter of our growth. Together with FGS, we are better equipped than ever to guide our clients through an increasingly complex world and a rapidly evolving stakeholder, financial, regulatory and political environment.”
Longview has been renamed FGS Longview and will continue to be led by Longview Partners Josh Pekarsky, Bruce Drysdale, Ian Hamilton and Hugh McFadyen. FGS Longview has offices in Toronto, Vancouver and Calgary, as well as team members in Ottawa, Winnipeg, Montreal and Victoria.
Andrew Cole, FGS’s Deputy Global Chief Executive Officer, added, “FGS was created to help leaders succeed in increasingly complex stakeholder ecosystems across industries and geographies. Clients want a strategic communications and advocacy partner who can advise and execute across the inter-connected financial, media, regulatory, and employee audiences in their home country and across the globe. We’re excited to partner with the Longview team and together help clients succeed in Canada and around the world.”
About Longview
Longview is Canada’s leading corporate communications and public affairs firm, with a seasoned team of professionals working together across disciplines to serve our clients’ interests. Our strategy is simple: do good work. Longview is top ranked in Canada, and the only Canadian firm consistently ranked among the top 15 PR advisors globally, on M&A transactions and shareholder activism. Longview serves clients from seven locations across Canada. The firm’s practice areas include Corporate & Financial Communications, Public Affairs, Special Situations and Design & Branding.
About FGS Global
FGS Global is a leading global strategic communications consultancy, with approximately 1,300 professionals around the world, advising clients in navigating complex situations and reputational challenges. FGS Global was formed from the combination of Finsbury, The Glover Park Group, Hering Schuppener and Sard Verbinnen to offer board-level and c-suite counsel in all aspects of strategic communications — including corporate reputation, crisis management, government affairs and is also the leading force in financial communications worldwide. The firm is backed by WPP Plc and KKR & Co. Inc.
FGS Global offers seamless and integrated support with offices in the following locations: Abu Dhabi, Amsterdam, Beijing, Berlin, Boston, Brussels, Chicago, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, Houston, Kingston, London, Los Angeles, Munich, Paris, Riyadh, San Francisco, Shanghai, Singapore, Tokyo, Washington, D.C., South Florida, and Zurich. Its headquarters is in New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121931472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
